This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Immunologic Disorders  • Multiple Sclerosis/ Demyelinating Disease  • Myasthenia Gravis  • Neuromuscular diseases  • Alert me on articles by topic

Vladimir Hachinski, MD, FRCPC, DSc
London, Ontario

Arch Neurol. 1999;56:1032.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A THERAPY used in a variety of disorders is bound to yield varying results. Sorensen thinks that intravenous immunoglobulin (IVIG) treatment is effective in Guillain-Barré syndrome. Karussis and Abramsky consider it an inferior choice that should be used only when plasmapheresis is contraindicated or unavailable. Sorensen thinks that IVIG should be used in chronic inflammatory demyelinating polyneuropathy. Karussis and Abramsky acknowledge this, but point out that some patients do not respond to IVIG, that the therapeutic effect fades in others, and that steroids remain the treatment-of-choice followed by plasmapheresis. All contributors agree that there is a role for IVIG in dermatomyositis and multifocal motor neuropathy. Its use in myasthenia gravis and Lambert-Eaton syndrome is less well founded, speculative in multiple sclerosis, and hazardous in neuromyotonia.

Karussis and Abramsky warn that IVIG derives from a large pool of individuals, making a mix of helpful antibodies unpredictable . . . [Full Text of this Article]

RELATED ARTICLES

Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes
Per Soelberg Sorensen
Arch Neurol. 1999;56(8):1025-1027.
EXTRACT | FULL TEXT  

Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No
Dimitrios Karussis and Oded Abramsky
Arch Neurol. 1999;56(8):1028-1032.
EXTRACT | FULL TEXT